MRK vs PFE
By Alex · Tickerpine
Merck & Company, Inc. vs Pfizer, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | MRK | PFE |
|---|---|---|
| Price | $132.92 | $26.31 |
| Market cap | $327.94B | $149.96B |
| P/E ratio | 106.3 | 35.1 |
| ROE | 6.96% | 5.01% |
| Profit margin | 4.77% | 6.80% |
| Revenue growth | 5.10% | 2.60% |
| Dividend yield | 2.56% | 6.46% |
| Beta | 0.21 | 0.28 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
MRK vs PFE in plain English
- MRK is the bigger company — about 2.2× the market cap of PFE.
- PFE is cheaper on earnings (P/E 35.1 vs 106.3).
- MRK earns a higher return on equity (7% vs 5%).
- MRK is growing revenue faster (5% vs 3%).
- PFE has the higher dividend yield (6.46% vs 2.56%).
How would $1,000 have done in each?
MRK return calculator
See what $1,000 in Merck & Company, Inc. would be worth today.
PFE return calculator
See what $1,000 in Pfizer, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.